Results 51 to 60 of about 5,563 (240)

Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia

Drugs in Context, 2020
Therapeutic options for relapsed/refractory B-cell acute lymphoblastic leukemia have evolved in the past few years. The FDA has approved three novel therapies for this disease: inotuzumab ozogamicin (an anti-CD22 antibody–drug conjugate), blinatumomab (a
Diego Conde-Royo, Luis Miguel Juárez-Salcedo, Samir Dalia   +2 more
doaj   +1 more source

Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager. [PDF]

iScience
Summary: Vγ9Vδ2 T cells constitute a homogeneous effector T cell population that lyses tumors of different origin, including the prostate. We generated a bispecific T cell engager (bsTCE) to direct Vγ9Vδ2 T cells to PSMA+ prostate cancer (PCa) cells. The
King LA, Veth M, Iglesias-Guimarais V, Blijdorp I, Kloosterman J, Vis AN, Roovers RC, Hulsik DL, Riedl T, Adang AEP, Parren PWHI, van Helden PM, de Gruijl TD, van der Vliet HJ.   +13 more
europepmc   +2 more sources

A rare case of B cell lymphoblastic leukemia with inv(7)(p15q34) with review of literature.

Leukemia Research Reports, 2021
The inv(7)(p15q34) chromosomal abnormality which juxtaposes part of the HOXA gene cluster on 7p15 to the TCRβ locus on 7q34, has been described in a subset of cases of T-cell lymphoblastic leukemia, but its presence in cases of B-cell lymphoblastic ...
Bernhisel Andrew, Orazi Attilio, Guar Sumit, Tonk Vijay, Ghafouri Sayed Reshad, Padilla Osvaldo   +5 more
doaj   +1 more source

Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report

JTO Clinical and Research Reports
A 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3–targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome but resulted in a
Shetal A. Patel, MD, PhD, Young Whang, MD, PhD, Chaely Medley, NP, Kevin Chen, PharmD, Jasmine Jordan, BS, Dante Bortone, PhD, Benjamin Vincent, MD, PhD, Jared Weiss, MD   +7 more
doaj   +1 more source

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers

Molecular Therapy: Oncolytics, 2023
Adoptive cell therapy (ACT) utilizing γδ T cells is becoming a promising option for the treatment of cancer, because it offers an off-the-shelf allogeneic product that is safe, potent, and clinically effective.
Scott A. Becker, Brian G. Petrich, Bing Yu, Kristopher A. Knight, Harrison C. Brown, Sunil S. Raikar, Christopher B. Doering, H. Trent Spencer   +7 more
doaj   +1 more source

Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V. [PDF]

Biomol Biomed
Kirsten Rat Sarcoma viral oncogene homolog (KRAS) is one of the most frequent oncogenes. However, there are limited treatment options due to its intracellular expression.
Lu C, Zou L, Wang Q, Sun M, Shi T, Xu S, Meng F, Du J.   +7 more
europepmc   +2 more sources

T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies. [PDF]

, 2022
Chimeric antigen receptor (CAR) T-cell and bispecific T-cell engager (BiTE) therapies have revolutionized the treatment of refractory or relapsed leukemia and lymphoma.
Ganatra, Sarju, Stein-Merlob, Ashley F, Yang, Eric H   +2 more
core  

Visualizing Spatial and Stoichiometric Barriers to Bispecific T-cell Engager EfficacyVisualizing Barriers to Bispecific T-cell Engager Efficacy [PDF]

, 2022
Bispecific T-cell engager (BiTE) molecules are biologic T cell-directing immunotherapies. Blinatumomab is approved for treatment of B-cell malignancies, but BiTE molecule development in solid tumors has been more challenging. Here, we employed intravital imaging to characterize exposure and pharmacodynamic response of an anti-muCD3/anti-huEGFRvIII ...
You, Ran, Artichoker, Jordan, Ray, Arja, Velozo, Hugo Gonzalez, Rock, Dan A, Conner, Kip P, Krummel, Matthew F   +6 more
openaire   +1 more source

Evaluation of an anti-CD3 VHH and construction of an anti-CD3/anti-EGFR bispecific tandem VHH as a cancer cell targeting drug construct

Biochemistry and Biophysics Reports
Recently, the development of T-cell engager cancer therapeutics, consisting of anticancer and anti-T-cell antibody parts to engage the T-cell to the cancer site, has gained interest.
Takuya Asanuma, Peiwei Ding, Yuki Kato, Takeshi Nakanishi, Ryutaro Asano, Koki Makabe   +5 more
doaj   +1 more source

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions

Frontiers in Oncology, 2023
Several key advances in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) over the past two decades have strategically exploited B-cell lineage markers suitable for targeting by immunotherapies. First, the addition of the anti-CD20 monoclonal antibody
David A. Russler-Germain, David A. Russler-Germain, Armin Ghobadi, Armin Ghobadi   +3 more
doaj   +1 more source